Paulo Gontero-Paolo

Turin, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 271 publications

Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.

Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.

Journal: European urology oncology
Published: December 12, 2025

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

Journal: European urology oncology
Published: November 17, 2025

The Winding Road to High-quality Transurethral Resection of the Bladder.

The Winding Road to High-quality Transurethral Resection of the Bladder.

Journal: European urology
Published: November 01, 2025

Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49.

Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49.

Journal: European urology
Published: February 19, 2025

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.

Journal: European urology
Published: July 11, 2024

A Restaging Transurethral Resection of the Bladder Is Always Necessary for High-grade T1 Non-muscle-invasive Bladder Cancer: Con.

A Restaging Transurethral Resection of the Bladder Is Always Necessary for High-grade T1 Non-muscle-invasive Bladder Cancer: Con.

Journal: European urology focus
Published: February 02, 2023

Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.

Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.

Journal: European urology
Published: January 04, 2023

Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?

Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?

Journal: European urology oncology
Published: June 28, 2022

Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.

Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.

Journal: European urology
Published: January 05, 2021

The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?

The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?

Journal: European urology
Published: April 07, 2020

Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.

Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.

Journal: European radiology
Published: December 19, 2019

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Journal: European urology
Published: July 27, 2019
Showing 1-12 of 271

Last Updated: 09/26/2026